Adicet Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACET research report →
Range $27 – $27
Price Chart
About the company
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies.
- CEO
- Chen Schor
- IPO
- 2018
- Employees
- 102
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on ACET
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.03M
- P/E
- -0.30
- Fwd P/E
- 9.73
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -69.71%
- ROIC
- -83.24%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-6,381,000+0.0%
- Op Income
- $-122,114,000
- Net Income
- $-116,803,000+0.3%
- EPS
- $-16.95+20.3%
- OCF Growth
- -3.1%
- FCF Growth
- -3.7%
- 52W High
- $11.15
- 52W Low
- $2.12
- 50D MA
- $5.38
- 200D MA
- $7.32
- Beta
- 1.69
- RSI (14)
- 13
- Avg Volume
- 260.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aceto’s quarter was pressured by Rising competition and launch delays, but management argued the Citron/Lucid acquisition materially expands its generic-drug pipeline and should accelerate growth after closing.· November 4, 2016
- Q1 fiscal 2017 sales were $128 million, down 4% year over year; gross profit was $30.8 million, down 10.8%, and gross margin fell to 24.1% from 25.9%.
- Human Health was the weak spot: sales were $47.9 million, down 16.7%, with gross profit down 30% and gross margin at 29.7% versus 35.3% a year ago.
- Pharma ingredients and Performance Chemicals both grew: Pharma ingredients sales were $40.6 million and Performance Chemicals sales were $39.5 million, with margin improvement in both segments.
- Management said Rising competition will continue for most of fiscal 2017 and product launch delays are pushing some expected revenue out of Q1 and Q2, with growth weighted to the second half.
- The Citron/Lucid deal adds scale, 47 commercial products, 31 approved-but-unlaunched products, 33 pipeline products, and management expects roughly $4 million of synergies by fiscal 2018.
- Guidance shifted lower standalone but better on a pro forma basis: without the deal, fiscal 2017 sales growth would be low single digits and adjusted EPS would be down mid-single digits; with the deal, sales growth is expected to be about 20% and adjusted EPS growth mid-single digits.
Aceto reported Q1 fiscal 2017 sales of $128 million, down 4% from $133.5 million a year ago. Gross profit was $30.8 million, down 10.8% from $34.6 million, and gross margin was 24.1% versus 25.9% last year. GAAP net income was $4.4 million, or $0.15 per share, versus $9.3 million, or $0.32 per share, and non-GAAP adjusted EPS was $0.28 versus $0.37. By segment, Human Health sales were $47.9 million, down 16.7%; Pharma ingredients sales were $40.6 million, up 5.9%; and Performance Chemicals sales were $39.5 million, up about 5%. For fiscal 2017, management said standalone sales growth is now expected to be low single digits and standalone non-GAAP adjusted EPS should be down mid-single digits, while pro forma including Citron the company expects sales growth of about 20% and adjusted EPS growth in the mid-single digits. GAAP EPS is expected to be below last year by about 20% because of transaction-related expenses and non-cash purchase accounting charges.
Sal Guccione said the quarter was hurt by Rising competition and delays in new product launches, and he acknowledged some of the launch slippage was due to supply-chain issues, validation/process issues, and slower FDA approvals. At the same time, he emphasized that Aceto still expects 12 to 15 launches in fiscal 2017 and that growth should be more heavily weighted to the second half. His tone was candid about near-term pressure but optimistic that the acquisition and product pipeline can restore momentum.
Doug Roth focused on the acquisition economics and financing. He said Citron and Lucid are projected to generate about $40 million of adjusted EBITDA on about $195 million of sales for the 12 months ended December 31, 2016, implying an 8.3x multiple on the $332 million net purchase price after expected tax benefits. He also outlined financing of $115 million drawn on the revolver, a new $150 million term loan, about $20 million of balance-sheet cash, 5.122 million restricted shares, and a $50 million deferred payment, with net covenant leverage at about 3.7x pro forma adjusted EBITDA and expected deleveraging of about a half-turn to three-quarters of a turn per year.
Analysts focused on how severe the Rising competition is, whether launch delays were driven by FDA or manufacturing issues, and whether Aceto can actually launch the large number of Citron products. Management said the competition is worse than expected on one major product and will affect results through the year, while launch delays reflect a mix of manufacturing-site issues, validation problems, and slower FDA approvals. They said the combined organization has the capability to launch most of the approved Citron products, but not necessarily all at once, and stressed that the Aurobindo supply arrangement remains in place after closing.
The acquisition substantially broadens Aceto’s generic-drug platform, increasing the pipeline from 100 projects to 164 and expanding approved products from 8 to 39. Management believes the deal is immediately accretive to non-GAAP EPS after closing, should add about $4 million of synergies by fiscal 2018, and positions Human Health for much larger scale and longer-term growth.
Near-term results are being pressured by stronger-than-expected competition in Rising and by supply-chain and approval delays that pushed some revenue out of Q1 and Q2. Management also said some of the lost revenue from delayed launches will likely not be recovered this year, and GAAP EPS will be pressured by transaction costs and purchase accounting charges.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.8%
- Shares Outstanding
- 9.36M
- Float Shares
- 8.22M
of shares held by institutions
59 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 932.62K | ▼ 250.00K |
| Orbimed Advisors LLC | 844.79K | ▼ 183.16K |
| Franklin Templeton Inc | 724.14K | ▲ 97.57K |
| Citadel Advisors LLC | 432.74K | ▲ 50.91K |
| Vanguard Capital Management LLC | 366.22K | ▲ 22.99K |
| Vanguard Group Inc | 291.28K | ▼ 2.98M |
| Adage Capital Partners Gp, L.L.C. | 274.38K | 0 |
| Renaissance Technologies LLC | 214.84K | ▼ 51.10K |
| Alyeska Investment Group, L.P. | 203.80K | 0 |
| Schonfeld Strategic Advisors LLC | 195.51K | ▲ 195.51K |
| Stonepine Capital Management, LLC | 188.20K | ▼ 57.32K |
| Carlyle Group Inc. | 184.29K | 0 |
Held by 25 ETFs
Biggest fund positions in ACET by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 5, 26 | Klickstein Lloyd | other | 18,300 |
| Jun 19, 26 | Schor Chen | other | 55,000 |
| Jun 19, 26 | Aftab Blake | other | 55,000 |
| Jun 21, 26 | DUBIN STEVE | other | 4,200 |
| Jun 21, 26 | Chodakewitz Jeffrey | other | 4,200 |
| Jun 21, 26 | Grissinger Michael | other | 4,200 |
| Jun 21, 26 | Sinclair Andrew | other | 4,200 |
| Jun 21, 26 | Peng Katie | other | 4,200 |
| Jun 21, 26 | Klickstein Lloyd | other | 4,200 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 250,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACET coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ACET?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
businesswire.com · Nov 5
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Oct 30
Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
marketbeat.com · Oct 2
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Sep 30
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
seekingalpha.com · Sep 28
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
businesswire.com · Sep 28
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
businesswire.com · Sep 25
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
zacks.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
